John Tan counsels clients on internal and government investigations, privacy and cybersecurity matters, and corporate compliance.

Mr. Tan brings a cross-disciplinary and cross-cultural perspective to his work, drawing on his experience as a trial and appellate lawyer and as in-house investigative counsel. He has advised clients across multiple industries and has particular experience in the life sciences and healthcare, automotive, and energy sectors. Clients describe Mr. Tan as "detailed" and "meticulous," and having "a very in-depth view of the Chinese legal system." His work includes counseling companies on the Foreign Corrupt Practices Act and other anti-corruption regulations, responding to government inquiries, developing compliance programs, and conducting compliance due diligence for corporate transactions. Mr. Tan also advises companies on privacy compliance and the creation of cross-border data strategies and assists companies in conducting data security and cybersecurity reviews.

Mr. Tan previously served as China Regional Compliance Director for Pfizer from 2010 to 2012.

Mr. Tan began his career as a public defender in the District of Columbia, where he handled numerous bench and jury trials and argued before the DC Court of Appeals five times. Mr. Tan has lived in Shanghai since 2005 and is fluent in Mandarin.


  • Multiple multinational companies in conducting investigations of whistleblower allegations in China and Asia relating to issues including:
    • allegations of corruption and other misconduct by clients' sales, marketing, procurement, and other functions
    • tenders for vaccines and capital equipment
    • revenue recognition
    • distributors, travel agencies, and other service providers
  • Major life sciences manufacturer in conducting pro-active reviews of their patient assistance programs.
  • Global pharmaceutical company in advising on privacy, data protection, and data security matters.
  • US-Chinese Joint Venture in conducting an internal review of transactions with state-owned media in China.
  • Leading multinational pharmaceutical manufacturer in an investigation into its GMP, quality, and supplier audit systems relating to the procurement of API.


China Again Ranks as a Top Source of Whistleblower Tips in 2020
Enforcement Edge: Shining Light on Government Enforcement
Analysis of China's Draft Personal Information Protection Law
Corporate Compliance and DOJ Guidance: Designing and Implementing Programs Tailored to Company Business and Culture
Panelist, Webinar
DOJ and SEC Release Second Edition of FCPA Guide
Corporate Compliance on the Cutting Edge: New Guidance from DOJ
Enforcement Edge: Shining Light on Government Enforcement


Chambers Global
Corporate Investigations/Anti-Corruption (China) (2015-2021)
The Legal 500 Asia-Pacific (2021)
Who's Who Legal
Global Investigations (2020)
China Life Sciences (2020)


  • JD, Georgetown University Law Center, 1998
  • Massachusetts Institute of Technology, 1993, Robert A. Muh Award for Undergraduate Research
  • District of Columbia
  • Virginia
  • Superior Court of the District of Columbia, The Honorable A. Franklin Burgess
  • Chinese (Mandarin)

Email Disclaimer